# JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

> **NCT00239681** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 17802 (actual)

## Conditions studied

- Elevated High-sensitivity C-Reactive Protein (hsCRP)

## Interventions

- **DRUG:** Rosuvastatin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00239681
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-02
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 17802 (ACTUAL)
- **Why stopped:** See detailed description for reason.
- **Last updated:** 2014-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239681, "JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00239681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*